{"id":2215,"date":"2025-05-19T16:38:39","date_gmt":"2025-05-19T16:38:39","guid":{"rendered":"https:\/\/juliashift.eu\/how-to-structure-your-womens-health-startup-before-raising-capital\/"},"modified":"2025-11-30T15:44:34","modified_gmt":"2025-11-30T15:44:34","slug":"how-to-structure-your-womens-health-startup-before-raising-capital","status":"publish","type":"post","link":"https:\/\/juliashift.eu\/en\/how-to-structure-your-womens-health-startup-before-raising-capital\/","title":{"rendered":"How to structure your women’s health startup before raising capital"},"content":{"rendered":"\n

How to structure a women’s health startup before raising capital<\/strong><\/h2>\n\n

Investors talk about inclusive startups, but what are they really looking at? Not the fine words, but the concrete, pre-raised structuring of a women’s health startup.<\/strong> Over the past three years, we have analyzed 40+ fund-raising files. Our findings are clear: successful female founders are not marketing feminism. They build inclusivity right from the code, patient architecture and governance. And that shows in the investor pitch. <\/p>\n\n

In this article, we look at five concrete players who have structured inclusivity as a structuring variable, long before they were looking for capital. Eva Ngall\u00e9 (TI3RS), H\u00e9l\u00e8ne Antier and Chlo\u00e9 Bonnet (Lyv.Endo), Emeline Hahn (Fizimed), and catalysts Delphine Moulu (Femtech France) and Iris Mar\u00e9chal (Theremia) trace different but converging paths. <\/p>\n\n

At the end, you’ll have a pre-raised framework audit<\/strong> to diagnose whether your women’s health startup is really ready and where investors are really looking.<\/p>\n\n

\"\"<\/figure>\n\n
\n\n

Sourcing disclaimer<\/strong><\/h3>\n\n

The cases and information presented below are based on public data (LinkedIn profiles, press articles, official websites). For precise confirmation of specific metrics or milestones, we recommend consulting the founders and teams mentioned directly. <\/p>\n\n

\n\n

Why investors scrutinize inclusivity pre-emptively<\/strong><\/h3>\n\n

Investors don’t value inclusiveness out of idealism. It is above all a variable for reducing operational and regulatory risk.<\/strong> Three concrete levers explain this. <\/p>\n\n

First lever: user adoption.<\/strong><\/p>\n\n

When a solution is co-designed directly with target users, rather than built in a silo and then validated afterwards, engagement naturally accelerates. Users involved from the outset become ambassadors for the product. Investors calculate: organic adoption means likely scalability. <\/p>\n\n

Second lever: regulatory compliance.<\/strong><\/p>\n\n

Since 2023, theANSM<\/a> (Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament) and the HAS<\/a> (Haute Autorit\u00e9 de Sant\u00e9) have been systematically asking the question: “Have you tested in mixed populations? Do you have gender-stratified results?” Startups that answer “yes, with documented proof” move forward faster. Access to French reimbursement is critical for healthcare start-ups. Investors see: tested inclusivity means de-risked compliance.<\/p>\n\n

Third lever: public funding.<\/strong><\/p>\n\n

BPI France<\/a>, Horizon Europe and ANR promote innovations that integrate inclusivity. For women’s health startups, this creates access to dedicated public capital. Investors see: public capital means reduced equity dilution for founders.<\/p>\n\n

Aggregate signal for investors:<\/strong> If a founder thought inclusivity from day zero, she thought adoption, compliance, and capital strategy. This changes the entire risk profile of the case. <\/p>\n\n

\n\n

Case 1 – Eva Ngall\u00e9 and TI3RS: a confidential support platform<\/strong><\/h3>\n\n

TI3RS is a digital support platform for women victims of violence, focusing on confidentiality and digital solutions.<\/p>\n\n

Structuring issues before lifting<\/strong> (according to our audit) :<\/p>\n\n